The Tonic-Clonic (Grand Mal) Seizure drugs in development market research report provides comprehensive information on the therapeutics under development for Tonic-Clonic (Grand Mal) Seizure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tonic-Clonic (Grand Mal) Seizure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tonic-Clonic (Grand Mal) Seizure and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Tonic-Clonic (Grand Mal) Seizure by seven companies/universities/institutes. The top development phase for Tonic-Clonic (Grand Mal) Seizure is phase iii with four drugs in that stage. The Tonic-Clonic (Grand Mal) Seizure pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Tonic-Clonic (Grand Mal) Seizure pipeline products market are: UCB, JC Pharma and SK Life Science.
The key targets in the Tonic-Clonic (Grand Mal) Seizure pipeline products market include Voltage Gated Sodium Channel (SCN), Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4), and Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2).
The key mechanisms of action in the Tonic-Clonic (Grand Mal) Seizure pipeline product include Voltage Gated Sodium Channel (SCN) Blocker with three drugs in Filing rejected/Withdrawn. The Tonic-Clonic (Grand Mal) Seizure pipeline products include three routes of administration with the top ROA being Oral and one key molecule types in the Tonic-Clonic (Grand Mal) Seizure pipeline products market including Small Molecule.
Tonic-Clonic (Grand Mal) Seizure overview
A tonic-clonic seizure, previously known as a grand mal seizure, is defined as a seizure that has a tonic phase followed by clonic muscle contractions that causes a loss of consciousness and violent muscle contractions.
For a complete picture of Tonic-Clonic (Grand Mal) Seizure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
